This study proves that there is no correlation between increased serum testosterone levels and PSA levels, thereby proving that castration-resistant prostate carcinoma does not undergo disease progression when treated using a high-dose testosterone replacement therapy [15]. Here, KLK3 is linked to prostate carcinoma.